Ace your next case

GPT-6 Luna The claim overstates what these sources support: symptoms alone, or a low-normal result, do not establish a need for testosterone therapy. Treatment is framed as replacement for pathological hypogonadism, with monitoring for benefit and safety. The supplied documents do not provide evidence that treating low-normal testosterone in young men reliably improves energy, mood or muscle.

DeepSeek V4.1 Flash The claim overstates the evidence. The documents support testosterone therapy for pathological hypogonadism, not for low-normal levels in young men without a defined hypothalamic-pituitary-testicular disorder. One review explicitly advises against prescribing testosterone to men with slightly low to low-normal levels and no identified disorder, citing uncertain cardiovascular risks and unproven health benefits. Symptom relief is the stated treatment aim, but benefits for energy, mood and muscle in this group are not established. Ageing-related decline is generally not a medical concern.

Grok 4.7 The claim is not supported. These sources reserve testosterone therapy for confirmed pathological hypogonadism, not young men with low-normal levels seeking more energy, mood or muscle. They advise against treatment when no hypothalamic-pituitary-testicular disorder is identified, citing uncertain cardiovascular risk and no proven benefit. Low testosterone can affect energy, mood and muscle, but age-related decline alone is not clearly a problem in healthy men. Therapy has risks, including reduced fertility and polycythaemia. Weight loss, exercise and treating underlying illness may help.

GPT-6 Luna The supplied evidence does not support diagnosing persistent tiredness as adrenal fatigue or treating it with adrenal supplements. It also does not mean tiredness is unexplained or unreal: other causes, including adrenal insufficiency, may need assessment. The review’s findings should be read alongside its methodological limitations.

DeepSeek V4.1 Flash The claim is not supported. Adrenal fatigue is not a recognised medical condition, and a systematic review found no substantiation for it. Cortisol studies show conflicting, inconsistent results. Persistent tiredness has many real causes, including iron deficiency, hypothyroidism and adrenal insufficiency, which need proper diagnosis. Adrenal supplements may be unsafe, can suppress natural hormone production, and stopping them suddenly risks adrenal crisis. They should not be used without medical advice. Clinically, evaluate fatigue for treatable causes rather than treating a presumed cortisol imbalance.

Grok 4.7 The claim is not supported. Adrenal fatigue is not a recognised medical condition, and a systematic review found no substantiation that chronic stress causes adrenal failure or that cortisol imbalance explains persistent tiredness. True adrenal insufficiency is rare, diagnosed by blood tests, and is distinct. Fatigue has many other causes, so assuming this diagnosis can delay proper assessment. Adrenal supplements are not proven effective and may be harmful, including by suppressing natural hormone production.

GPT-6 Luna “Harmless” is too reassuring: unregistered gummies can contain unpredictable amounts, and children may face risks including accidental overdose or serious side effects. The evidence supplied does not show that every melatonin product is harmful; it supports caution, medical oversight and distinguishing regulated medicines from unregistered supplements.

DeepSeek V4.1 Flash The claim is not supported. Australian melatonin use in children is prescription-only for limited indications, with broader use not assessed for safety or efficacy. TGA testing found imported gummies with up to 417% of labelled content, and some with no melatonin. A US study found 22 of 25 gummies inaccurately labelled, mostly exceeding declared amounts. Paediatric use carries risks including accidental overdose and hospitalisation, and seizure disorders may worsen. Gummies are not harmless; use should involve a doctor and regulated products.

Grok 4.7 The claim is not supported. In Australia, melatonin is approved for children only as a prescription medicine for insomnia in autism spectrum disorder and/or Smith-Magenis syndrome, ages 2 to 18. Broader paediatric safety and efficacy have not been evaluated. Imported gummies are often unregistered. Testing found doses from none to more than four times the label, with overdose, hospitalisation, and possible increased seizures reported. A small US study also found widespread mislabelling and some CBD. These findings do not assess every regulated prescription product. Use requires clinician oversight, not unsupervised gummies.

GPT-6 Luna The claim overstates both who these medicines are for and how safely they can be used. The supplied evidence describes approved treatment groups and meaningful risks, but does not show that injections are appropriate for anyone or a shortcut free of trade-offs. Suitability and expected benefit depend on individual clinical circumstances.

DeepSeek V4.1 Flash The claim is not supported. These medicines are approved in Australia for type 2 diabetes or for chronic weight management in people who are obese or overweight, not for general use. They are not "safe shortcuts". Safety concerns include delayed gastric emptying and pulmonary aspiration risk under anaesthesia or deep sedation, even with fasting. Trials in non-diabetic people with obesity or overweight show increased nausea, vomiting, diarrhoea and constipation. Evidence covers defined populations only, and trials include lifestyle support; it does not support use without an indication.

Grok 4.7 The claim is not supported. Australian approvals cover selected GLP-1 and dual GIP/GLP-1 medicines for type 2 diabetes and, for some products, chronic weight management in obesity or overweight, not use by anyone without an indication. Trial evidence concerns adults with obesity, or overweight plus a complication. Gastrointestinal effects are common, and delayed gastric emptying creates an aspiration risk during anaesthesia or deep sedation. Comparable trial safety does not mean unrestricted safety. These medicines are adjuncts to diet and activity, not a shortcut.

GPT-6 Luna The key distinction is between an association across varied fluoride exposures and proof that community fluoridation at Australian levels lowers IQ. The supplied sources do not establish that causal claim. NHMRC's assessment is reassuring for Australian levels, but it dates to 2016, while newer research has renewed scientific scrutiny.

DeepSeek V4.1 Flash The claim overstates the evidence. NHMRC states there is no reliable evidence that fluoridation at current Australian levels causes health problems. US NTP reviews report an inverse association between higher fluoride exposure and children's IQ, with moderate confidence, including some high-quality studies below 1.5 mg/L. However, much evidence comes from higher-exposure regions, many studies are cross-sectional or lower quality, and findings are observational. It does not establish that Australian community fluoridation lowers IQ, and causality remains uncertain.

Grok 4.7 The claim is not supported for community water fluoridation at current Australian levels. NHMRC’s 2016 review found fluoridation reduces tooth decay and no reliable evidence that Australian levels cause health problems. Separate reviews report an inverse association between higher fluoride exposure and children’s IQ, including some analyses below 1.5 mg/L. Much of that evidence is observational, often from higher exposures, and quality is mixed; one review found negative findings mainly in poorer studies. Association is not proof that Australian fluoridation lowers IQ. Clinical decisions should not treat this claim as established.

GPT-6 Luna The claim combines two questions that the supplied evidence does not support equally. The evidence strongly contradicts raw milk being safer: it can contain disease-causing organisms that pasteurisation is designed to kill. The claimed health advantage is less settled; reported possible benefits do not establish that raw milk is healthier overall or outweigh its infection risks.

DeepSeek V4.1 Flash The claim is not supported. FSANZ concluded raw milk risks are too great to relax pasteurisation requirements, citing Campylobacter, Listeria, Salmonella, E. coli O157 and Cryptosporidium, with severe complications and outbreaks in Australia and abroad. One review found raw dairy outbreaks caused more confirmed cases, hospitalisations and deaths than pasteurised products. Raw milk offers no demonstrated safety advantage. A second review notes possible allergy-related associations but cannot conclude benefits outweigh risks. Pasteurised milk retains equivalent nutrients. Applicability: pasteurisation remains the standard public health safeguard, especially for children, pregnancy and immunocompromise.

Grok 4.7 The claim is not supported. Australian food-safety assessment finds raw milk can contain Campylobacter, Listeria, Salmonella, pathogenic E. coli and Cryptosporidium, with severe illness including kidney failure, paralysis and death. Hygiene does not reliably remove these pathogens, and outbreaks continue. Pasteurised dairy is not risk-free: contamination after processing, especially with Listeria, can cause serious outbreaks. Available evidence indicates nutrients are broadly equivalent. Reported links with less asthma or atopy are not proof that raw milk is healthier or that benefits outweigh infection risk. Clinically, pasteurised milk remains the safer choice, particularly for children, older adults, pregnant people and immunocompromised patients.

GPT-6 Luna The memory signal is not enough to support the full claim: the meta-analysis included mixed populations, and the later methodological critique raises a substantial concern about its analysis. Evidence here does not confirm a benefit specifically in healthy adults, and “brain fog” was not measured.

DeepSeek V4.1 Flash The meta-analysis reports a small memory benefit (SMD 0.24) from creatine, but this is low-certainty evidence and not specific to healthy adults: it pooled healthy people with clinical populations, and effects were larger in those with disease. "Brain fog" was not measured. A commentary notes a methodological flaw (counting multiple tests from the same participants as independent), which inflates precision; a similar reanalysis removed the memory effect, and an EFSA panel judged the evidence inconclusive. Bottom line: a modest, uncertain memory signal, not a proven cognitive enhancer for healthy people.

Grok 4.7 The claim is only partly supported and overstated. A 2024 meta-analysis of 16 trials reported a small memory benefit from creatine monohydrate, with moderate-certainty evidence, plus possible effects on attention and processing speed. Benefits appeared greater in people with disease than in healthy adults. Overall cognition and executive function did not improve. A later commentary identified double-counting of related test results, which can inflate significance. EFSA concluded that no cognitive claim could be drawn from those data. Brain fog was not assessed. Evidence does not justify routine use in healthy adults.

GPT-6 Luna The supplied evidence does not support a broad claim that linoleic-acid-rich vegetable oils cause inflammation, but it is limited and does not settle every question about seed oils or health. The wording “toxic” is broader than what these trials assessed.

DeepSeek V4.1 Flash The claim that linoleic-rich oils such as canola and sunflower cause inflammation is not supported. A systematic review of 15 controlled trials found no effect of varying linoleic acid intake on CRP or other inflammatory markers, and some studies suggested inverse associations. However, trials were small (maximum 40 participants), short (up to 40 days), and often used surrogate markers, so a subtle effect cannot be fully excluded. The evidence does not support calling these oils toxic. The document is an abstract-level commentary; the full paper should be checked before firm conclusions.

Grok 4.7 The supplied review does not support calling canola or other linoleic acid-rich vegetable oils toxic or inflammatory. A systematic review of 15 randomized trials found no significant effect of varying linoleic acid intake on CRP or other inflammatory markers in healthy people. Observational data often showed inverse or no associations. Evidence is limited by small samples, short trials, and uncertain biomarker relevance, so an inflammatory effect cannot be fully excluded. Current guidance cited supports 5–10% of energy from polyunsaturated fats, including linoleic acid, as a replacement for saturated and trans fats. Sunflower oil is not specifically assessed.

GPT-6 Luna The supplied evidence does not support the claim that high LDL is protective or that lowering it is unnecessary. The strongest source synthesises several types of evidence for a causal role and benefit from lowering LDL. Treatment decisions still depend on a person’s overall cardiovascular risk; these documents do not establish that every person needs the same target or treatment.

DeepSeek V4.1 Flash The claim is not supported. All three documents describe LDL cholesterol as causally implicated in atherosclerosis, with Mendelian randomisation and trials showing that lowering LDL-C reduces cardiovascular events. The meta-analysis found LDL-C of 130 mg/dL or higher associated with higher all-cause mortality and cardiovascular risk; it did not show harm from low LDL-C. No document supports a protective effect. Limitations: these are cohorts, a review and an opinion piece, not a dedicated trial of the claim. Applies to adults; targets are for high-risk and secondary prevention.

Grok 4.7 The claim is not supported. Australian and trial evidence treat high LDL cholesterol as causal in atherosclerosis. Lowering it reduces heart attack, stroke, and cardiovascular death, with about a 20 to 25 percent relative-risk reduction per 1 mmol/L fall. Very low achieved levels have not shown harm in major treatment trials. Some observational cohorts report higher all-cause mortality at low LDL, but that does not show high LDL is protective or make lowering unnecessary. Benefit is greatest after atherosclerotic events; targets and combinations should follow guidelines and individual risk, not be stopped abruptly.

GPT-6 Luna The blanket claim is not supported by these documents: they describe cardiovascular benefit alongside recognised possible harms. The evidence supplied is not a complete assessment of every patient group or individual risk profile. Concerns about side effects deserve attention, but this claim alone is not a reason to stop treatment without discussing options with a clinician.

DeepSeek V4.1 Flash The claim is not supported. The review describes statins as first-line therapy that cuts cardiovascular events by about 20% per 1 mmol/L LDL reduction, with adverse reactions mostly uncommon; muscle symptoms are the main issue but placebo-controlled trials show little difference from placebo, suggesting a nocebo effect. It notes statin intolerance in some patients, so monitoring and management are needed, not avoidance. The exercise review found only a small, non-significant excess of muscle symptoms with statins. Neither document supports stopping statins; decisions should be individualised with a clinician.

Grok 4.7 The claim is not supported. Both reviews describe real harms, including muscle symptoms, liver effects, and diabetes risk, and note that intolerance can reduce adherence. They also report substantial benefit: roughly a 20 to 22 percent reduction in cardiovascular events for each 1 mmol/L fall in LDL cholesterol. Muscle symptoms are much less common in blinded trials than observational reports, with many attributed to nocebo effects. These sources do not show net harm or support avoiding or stopping statins in people at heart-disease risk. Do not stop treatment abruptly without clinical review.

GPT-6 Luna Communicate the risk as a possible, uncommon adverse effect—not as an inevitable outcome or evidence that prescribed treatment is equivalent to non-medical stimulant use. Explain that available studies are observational and do not establish causation or directly compare prescribed with non-medical use. Invite questions and discuss concerns in the context of the person’s treatment and circumstances.

DeepSeek V4.1 Flash The claim asks how to communicate psychosis risk from prescribed stimulants while separating it from non-medical use. The documents address prescribed ADHD medication only. One pharmacovigilance study found higher reporting of psychotic symptoms with amphetamines than methylphenidate; a cohort study found low absolute risk but higher risk with amphetamines and atomoxetine. Neither document examines non-medical stimulant use, so that distinction is not supported here. Both are observational and cannot establish causation; confounding by indication or severity is possible. Communication should note low absolute risk, agent differences, and monitoring, without implying equivalence to illicit use.

Grok 4.7 These sources concern prescribed ADHD medicines, not non-medical stimulant use or communication methods. They support a higher relative reporting or diagnosis of psychotic symptoms with amphetamines than methylphenidate, and mixed atomoxetine findings; absolute risk in one youth cohort was low at 2.6%. Both are observational, so confounding by ADHD severity, prodrome, or polypharmacy remains possible. Clinicians can explain this uncertainty and individual benefit–risk without equating prescribed treatment with misuse or advising abrupt cessation.

GPT-6 Luna The case reports and uncertain product contents justify clear, non-judgemental conversations about potential harm, while avoiding claims that quantify an individual’s risk. Ask about use directly, explain that reactions can occur even after previous uneventful doses, and encourage prompt emergency care for possible anaphylaxis. The Victorian advisory specifically recommends open discussion and notification of suspected adverse effects.

DeepSeek V4.1 Flash Supported: Victoria has notified 13 anaphylaxis cases linked to unapproved peptides since July 2025, including a September 2026 cluster, versus one case since 2018. The claim's reported death is not mentioned in either document. Most cases were first episodes, and reaction can occur after uneventful prior doses. TGA advises unapproved peptides are unevaluated for safety, quality or effectiveness, with risks including liver damage and severe allergy. Clinical applicability: discuss use openly and without judgement, advise immediate emergency care for anaphylaxis symptoms, avoid abrupt cessation advice, and report adverse events to TGA.

Grok 4.7 The Victorian advisory supports a cluster of five anaphylaxis notifications in September 2026 among 13 peptide-linked cases since July 2025. It does not report a death. Unapproved peptides are not TGA-assessed for safety, quality, or effectiveness, and risks include anaphylaxis, infection, organ toxicity, and liver injury. This is an active health advisory, not a treatment guideline. Clinicians should discuss use openly and without judgement, warn that anaphylaxis can be fatal and needs emergency care, support safer approved options, and report adverse events.